AMP Capital Investors Ltd lifted its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,886 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the period. AMP Capital Investors Ltd’s holdings in Alexion Pharmaceuticals were worth $11,588,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Delpha Capital Management LLC purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth about $102,000. Valeo Financial Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $147,000. Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $156,000. Beacon Investment Advisory Services Inc. purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $201,000. Finally, Invictus RG purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth about $202,000. 95.38% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Alexion Pharmaceuticals, Inc. (ALXN) opened at $121.08 on Wednesday. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34. The firm has a market cap of $26,840.00, a PE ratio of 55.80, a price-to-earnings-growth ratio of 1.16 and a beta of 1.13. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.39. The company had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a net margin of 8.36% and a return on equity of 3.42%. Alexion Pharmaceuticals’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.26 EPS. equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current fiscal year.

A number of analysts have recently commented on the stock. Evercore ISI raised shares of Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research note on Monday, February 5th. Leerink Swann lowered their price target on shares of Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Raymond James Financial restated an “outperform” rating and set a $130.00 price target (down from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. Cowen restated a “buy” rating and set a $163.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, March 9th. Finally, Robert W. Baird upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price target on the stock in a research report on Monday, December 18th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty have issued a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $154.64.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at approximately $4,399,600.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Paul J. Clancy sold 6,079 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $707,048.49. Following the completion of the transaction, the chief financial officer now owns 95,093 shares in the company, valued at $11,060,266.83. The disclosure for this sale can be found here. Insiders sold a total of 31,253 shares of company stock worth $3,656,229 over the last quarter. 4.35% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “AMP Capital Investors Ltd Grows Stake in Alexion Pharmaceuticals, Inc. (ALXN)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/03/14/amp-capital-investors-ltd-grows-stake-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.